Immune Pharmaceuticals Current Ratio vs. Working Capital
Based on Immune Pharmaceuticals' profitability indicators, Immune Pharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in May. Profitability indicators assess Immune Pharmaceuticals' ability to earn profits and add value for shareholders.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
Please note, there is a significant difference between Immune Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immune Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immune Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
For Immune Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immune Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immune Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immune Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immune Pharmaceuticals over time as well as its relative position and ranking within its peers.
Immune |
Immune Pharmaceuticals Working Capital vs. Current Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Immune Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Immune Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Immune Pharmaceuticals is currently regarded as number one stock in current ratio category among related companies. It is currently regarded as number one stock in working capital category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immune Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immune Pharmaceuticals' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immune Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Immune Working Capital vs. Current Ratio
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Immune Pharmaceuticals |
| = | 0.02 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Immune Pharmaceuticals |
| = | (1.45 M) |
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Immune Working Capital Comparison
Immune Pharmaceuticals is currently under evaluation in working capital category among related companies.
Immune Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immune Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immune Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Immune Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Immune Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. Immune Pharmaceuticals operates under Drug Manufacturers - Major classification in USA and is traded on BATS Exchange. It employs 7 people.
Immune Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Immune Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immune Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immune Pharmaceuticals' important profitability drivers and their relationship over time.
Use Immune Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immune Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immune Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Immune Pharmaceuticals Pair Trading
Immune Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Immune Pharmaceuticals position
In addition to having Immune Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Thematic Idea Now
Precious Metals
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Precious Metals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Immune OTC Stock
If you are still planning to invest in Immune Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Pharmaceuticals' history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| CEOs Directory Screen CEOs from public companies around the world |